Special
Researchers Engineer “Mini” CRISPR-Cas System That Could Act as ‘Swiss Army Knife’ for Mammalian Genome Editing
2021-09-07
Feng Zhang’s Team Engineer “Ultra-Compact” Cas-13 To Solve Packaging and Delivery Issues of RNA Editors
2021-09-05
Current Challenges and Future Opportunities of Artificial RNA Editing – An Interview with Professor Toshifumi Tsukahara
2021-08-26
Addressing The Global Need for Biosimilars: Current Trends, Expectations and Real World Experiences
2021-08-26
Years After Playing Second Fiddle to CRISPR, RNA Editing Comes Into Its Own – An Interview with Dr. Joshua Rosenthal
2021-08-25
HebaBiz Biotech Obtains FDA Clearance to Trial Cancer Drug Against Aggressive Brain Tumor
2021-08-22
Innovent Announces Gastric Cancer Trial Win for Tyvyt, Reveals Plans for Another China Approval
2021-08-16
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115